Funda Meric, MD
Surgery · Houston, TXNPI 1306932074
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $115,070 of the $141,289 with a category attached, or 81.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2024 at $40,845 and has fallen 52.5% since, to $19,412 in 2025. Among surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $1158.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$29K
- F. Hoffmann-la Roche AG$28K
- Daiichi Sankyo Inc.$20K
- AstraZeneca$17K
- Theratechnologies Inc.$7K
- Boehringer Ingelheim International GmbH$6K
- plus $35K from 19 others
Across 730 payments — averaging $28,017 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Company LTD$4.3M
- AstraZeneca$3.7M
- Daiichi Sankyo Inc.$3M
- Novartis$1.8M
- Taiho Oncology, Inc.$1.3M
- Pfizer$1.1M
- plus $5.2M from 16 others
What the payments were for
- Consulting fees$115,07081%
- Speaking & faculty fees$5,2674%
- Travel & lodging$16,61412%
- Food & beverage$4,3383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 25 | $28,585 |
| F. Hoffmann-la Roche AG | 8 | $28,155 |
| Daiichi Sankyo Inc. | 24 | $19,519 |
| AstraZeneca | 14 | $17,321 |
| Theratechnologies Inc. | 8 | $7,106 |
| Boehringer Ingelheim International GmbH | 1 | $6,090 |
| Incyte Corporation | 5 | $6,000 |
| Karyopharm Therapeutics Inc. | 1 | $5,000 |
| Sanofi | 4 | $4,580 |
| Seagen Inc. | 7 | $3,829 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,828 |
| Eisai Inc. | 1 | $3,594 |
| Pfizer(2 entities) | 4 | $2,704 |
| Eli Lilly | 1 | $1,750 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $1,201 |
| Tempus AI, Inc | 1 | $1,000 |
| Jazz Pharmaceuticals Inc. | 4 | $346 |
| Lexicon Pharmaceuticals, Inc. | 2 | $143 |
| Stemline Therapeutics Inc. | 1 | $124 |
| Puma Biotechnology, Inc. | 3 | $102 |
| Blueprint Medicines Corporation | 1 | $98 |
| Novartis | 1 | $98 |
| Exelixis Inc. | 1 | $74 |
| Amgen | 1 | $24 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,289 in reported general payments places this provider in the 95th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgery in Houston
- James SuliburkHouston$161K
- Jonathan StahlHouston$105K
- Richard KnightHouston$103K
- Tanyaradzwa KajeseHouston$92K
- Michael HarkinsTomball$2.7M
- Douglas StoddardAustin$1.4M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$851K
- Andy HawthorneRound Rock$843K
- Nancy MarquezAustin$700K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.